Recent News Releases

For investor-related news, see our ASX releases here.

Month Year

Email Alerts

Sep 24, 2024

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan
Sep 13, 2024

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®,...
Jun 11, 2024

CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU

CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...
May 30, 2024

On Pandemic Preparedness

Throughout 2023 and 2024, outbreaks of highly pathogenic avian influenza (HPAI) viruses among birds have been reported in several regions including Africa, Asia, Europe, and North America...
May 20, 2024

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior...

Show per page

Filter by Company:

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa